MedTrace Logo

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

NCT05322187 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-04-11

No results posted yet for this study

Summary

This is a single arm, open-label trial studying the combination of PD-1/PD-L1 Inhibitor (e.g.pembrolizumab, Sintilimab,Duvarizumab，Camrelizumab )and lenvatinib given at the recommended dose in pediatric and young adolescent patients((5 year-old\<age\<14 year-old) with TLCT or refractory hepatoblastoma after chemotherapy.

Conditions

  • Transitional Cell Tumor
  • Hepatoblastoma
  • Liver Cancer
  • Pediatric Solid Tumor
  • Pediatric Cancer

Interventions

DRUG

PD-1 inhibitor

Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Hao Feng · Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

  • Qiang Xia · Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-10
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322187 on ClinicalTrials.gov